Opportunities and challenges of antiangiogenic therapy for biliary tract tumors
10.3760/cma.j.cn113884-20250204-00038
- VernacularTitle:抗血管生成靶向药物治疗胆道肿瘤的机遇与挑战
- Author:
Yiwen ZHOU
1
;
Shurui ZHOU
;
Jieer YING
Author Information
1. 浙江中医药大学第二临床医学院，杭州 310053
- Publication Type:Journal Article
- Keywords:
Biliary tract tumor;
Targeted therapy;
Immunotherapy;
Tumor microenvironment
- From:
Chinese Journal of Hepatobiliary Surgery
2025;31(9):715-720
- CountryChina
- Language:Chinese
-
Abstract:
Biliary tract tumor (BTC) often present insidiously and are highly aggressive, with most cases diagnosed at an advanced stage, resulting in poor prognosis. Targeted anti-angiogenic drugs have been approved for the treatment of various cancers and have been applied to patients with BTC. This article summarizes the latest research advances in the use of targeted anti-angiogenic drugs for the treatment of BTC, analyzes the efficacy of targeted anti-angiogenic drugs as monotherapy and in combination with chemotherapy and immunotherapy for BTC, and discusses the challenges and future directions in their application in BTC, aiming to provide guidance for clinical diagnosis and treatment of BTC.
